Suppr超能文献

2005 年至 2018 年期间中国南京 HIV 感染者的生存状况及其与死亡率相关的因素分析。

Survival and risk factors associated with mortality in people living with HIV from 2005 to 2018 in Nanjing, China.

机构信息

Department of AIDS and STDs Control and Prevention, Nanjing Municipal Center for Disease Control and Prevention, Nanjing, China.

Department of Microbiological Test, Nanjing Municipal Center for Disease Control and Prevention, Nanjing, China.

出版信息

Front Public Health. 2022 Oct 19;10:989127. doi: 10.3389/fpubh.2022.989127. eCollection 2022.

Abstract

BACKGROUND

Although the introduction of antiretroviral therapy (ART) decreased the mortality of people living with Human Immunodeficiency Virus (PLHIV), substantially, hundreds of thousands of people are dying of AIDS each year. The accurate survival patterns and factors related to death among PLHIV were rarely reported. In this study, we evaluated survival status and identified factors associated with death among PLHIV in Nanjing.

METHODS

We conducted a retrospective analysis of PLHIV followed-up in Nanjing and registered to the national HIV/AIDS comprehensive management information system from 2005 to 2018. We used the life table to calculate the cumulative survival rates. We applied the Kaplan-Meier to calculate median survival times and employed cox hazard proportional regression to analyze the associated factors related to death.

RESULTS

The median survival time of PLHIV was 11.8 (95%:11.6-11.9) years from 2005 to 2018. Among 4,235 PLHIV included in this study, 7.5% had died of AIDS-related disease and the AIDS-related mortality rate was 2.0/100 PYs. The cumulative proportion surviving at the end of the interval was 95.2% over the 1st year, 94.0% over the 2nd year, 91.8% over the 5th year, and 85.4% over the 10th year, respectively. PLHIV who unaccepted ART showed a greater risk of death compared to those who accepted ART (AHR = 16.2, 95%:11.922.2). For baseline CD4 count, compared to CD4 < 200 cell/μL, higher CD4 count was demonstrated as a protective factor, with = 0.2 (95%: 0.10.3) for ≥500 cell/μL, = 0.3 (95%:0.20.4) for 350499 cell/μL, = 0.4 (95%:0.30.6 for 200349 cell/μL). In addition, we observed a higher death risk in PLHIV who were screened through outpatient ( = 1.6, 95%: 1.12.2) and inpatient ( = 1.6, 95%CI: 1.12.5) compared to through VCT; the age of diagnosis was ≥50 years old ( = 9.5, 95%: 3.724.1) and 2549 years old ( = 5.0, 95%: 2.012.3) compared to ≤ 24 years old; educated from junior and below ( = 3.4, 95%: 2.35.1) and Senior high school ( = 1.7, 95%: 1.1~2.7) compared to college and above.

CONCLUSION

The AIDS-related mortality among PLHIV in Nanjing was relatively low. A higher risk for AIDS-related deaths were observed among PLHIV who unaccepted ART, whose baseline CD4 cell count was<200 cell/μL, older age, and lower educated.

摘要

背景

尽管抗逆转录病毒疗法(ART)的引入大大降低了人类免疫缺陷病毒(PLHIV)患者的死亡率,但每年仍有数十万人死于艾滋病。PLHIV 的准确生存模式和与死亡相关的因素很少有报道。在这项研究中,我们评估了南京 PLHIV 的生存状况,并确定了与死亡相关的因素。

方法

我们对 2005 年至 2018 年在南京接受随访并登记到国家艾滋病综合管理信息系统的 PLHIV 进行了回顾性分析。我们使用生命表计算累积生存率。我们应用 Kaplan-Meier 计算中位生存时间,并采用 Cox 比例风险回归分析与死亡相关的因素。

结果

从 2005 年到 2018 年,PLHIV 的中位生存时间为 11.8(95%置信区间:11.6-11.9)年。在纳入本研究的 4235 名 PLHIV 中,有 7.5%死于艾滋病相关疾病,艾滋病相关死亡率为 2.0/100 人年。在随访间隔结束时,存活的累积比例分别为第 1 年为 95.2%,第 2 年为 94.0%,第 5 年为 91.8%,第 10 年为 85.4%。与接受 ART 的 PLHIV 相比,未接受 ART 的 PLHIV 死亡风险更高(AHR=16.2,95%置信区间:11.922.2)。对于基线 CD4 计数,与 CD4<200 个细胞/μL 相比,较高的 CD4 计数被证明是一个保护因素,CD4≥500 个细胞/μL 的 =0.2(95%置信区间:0.10.3),350499 个细胞/μL 的 =0.3(95%置信区间:0.20.4),200349 个细胞/μL 的 =0.4(95%置信区间:0.30.6)。此外,我们发现通过门诊( =1.6,95%置信区间:1.12.2)和住院( =1.6,95%置信区间:1.12.5)筛查的 PLHIV 死亡风险高于通过 VCT 筛查的 PLHIV;诊断年龄≥50 岁( =9.5,95%置信区间:3.724.1)和 2549 岁( =5.0,95%置信区间:2.012.3)高于≤24 岁;受教育程度为初中及以下( =3.4,95%置信区间:2.35.1)和高中( =1.7,95%置信区间:1.1~2.7)高于大学及以上。

结论

南京 PLHIV 的艾滋病相关死亡率相对较低。未接受 ART、基线 CD4 细胞计数<200 个细胞/μL、年龄较大和受教育程度较低的 PLHIV 发生艾滋病相关死亡的风险更高。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9f2a/9627204/752087e91afb/fpubh-10-989127-g0001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验